
A potential financial relationship between investigators and pharmaceutical manufacturers has been associated with an increased likelihood of reporting favorable conclusions about a zzso proprietary agent in zzso zzso The purpose of this study is to investigate whether there is an association between financial relationships and outcome in economic analyses of new targeted therapies in zzso 

We searched zzso zzso update June zzso for economic analyses of targeted therapies (including zzso zzso zzso zzso and zzso target of zzso zzso in zzso The trials were zzso rated regarding the cost assessment as zzso neutral, or zzso on the basis of zzso zzso 

Overall, 81 eligible studies were zzso Economic analyses that were zzso by pharmaceutical companies were more likely to report favorable qualitative cost estimates zzso zzso of 34 v 21 zzso of zzso P zzso zzso The presence of an author affiliated with manufacturer was not associated with study zzso Furthermore, if only studies including a conflict of interest statement were included zzso of zzso studies that reported any financial relationship with manufacturers zzso affiliation and/or funding and/or other financial zzso were more likely to report favorable results of targeted therapies compared with studies without financial relationship (32 zzso of 45 v nine zzso of zzso P zzso zzso 

Our study reveals a potential threat for zzso bias in economic analyses of targeted therapies in zzso in favor of analyses with financial relationships between authors and zzso A more balanced funding of economic analyses from other sources may allow greater confidence in the interpretation of their zzso 

